Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Recurrent Glioblastoma Clinical Trial

Official title:

Phase 0/I Dose Escalation Study of Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04477200
• Other study ID #: UMCC 2019.192
• Secondary ID: HUM00175785R37CA
• Status: Recruiting
• Phase: Phase 1
• Start date: August 5, 2020
• Est. completion date: October 2027

Study information

• Verified date: June 2023
• Source: University of Michigan Rogel Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.

Description:

The goal of the Phase 0 component is to determine if MMF achieves active concentrations in brain tumors. Eight participants in Phase 0 will receive MMF for one week before undergoing an already planned biopsy or re-resection (surgical removal) of glioblastoma or gliosarcoma (GBM/GS). A small portion of the tumor, removed as part of clinical care, will be used for testing in this study. Sixty additional participants will be enrolled in the Phase 1 component of the trial (30 with recurrent GBM/GS and 30 with newly diagnosed GBM/GS). The goal of the Phase 1 component is to find the dose of MMF that works best without causing severe side effects (the maximum tolerated dose) when combined with radiation in recurrent GBM/GS and with radiation and chemotherapy in newly diagnosed GBM/GS. Participants in Phase 0 who meet the eligibility criteria for the Phase 1 component may participate in both phases.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 68
• Est. completion date: October 2027
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Glioblastoma or gliosarcoma (recurrent or newly diagnosed).

• Karnofsky Performance Status 60 or greater.

• Phase 0: Candidate for clinically indicated re-resection or biopsy of glioblastoma or gliosarcoma per treating physician(s).

• Phase 1, Recurrent: Candidate for clinically indicated re-irradiation of glioblastoma or gliosarcoma per treating physician(s) (No more than one prior course of radiation for GBM).

• Phase 1, Newly Diagnosed: Candidate for upfront standard of care chemoradiation for glioblastoma or gliosarcoma per treating physician(s), to start no earlier than 14 days post- operatively from last definitive surgery for glioblastoma or gliosarcoma (if more than one surgery done. Ex. biopsy prior to resection).

• ANC >=1,500 cells/mm^3 within 14 days prior to enrollment.

• Patient (men and childbearing age women) agrees to the use of highly effective contraception during study participation and for at least 6 weeks for female patients and 90 days for male patients after final MMF administration.

• Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

• Lack of histopathological diagnosis of the tumor.

• Gliomatosis cerebri pattern (tumor involving 3 or more lobes) of disease.

• Leptomeningeal disease.

• Use of bevacizumab within 8 weeks of study enrollment.

• Known history of HIV.

• Active hepatitis B or C infection.

• Active systemic or central nervous system (CNS) infection.

• Grade 4 lymphopenia (if ALC <0.5, patient must be on Pneumocystis jirovecii prophylaxis).

• Estimated CrCl < 25 ml/min.

• History of organ transplantation.

• Patients with known hypoxanthine-guanine phosphoribosyl-transferase deficiency.

• Serious intercurrent disease.

• History of allergic reaction or hypersensitivity to mycophenolate mofetil or mycophenolic acid or any component of the drug product; or medical contraindication for MMF per treating physician(s).

• Known immunosuppressive condition from autoimmune disease, immune deficiency syndrome, or chronic immunosuppressive therapy.

• Inability to undergo MRI brain with and without contrast.

• Pregnant or lactating women.

• Patients with known phenylketonuria.

• Phase 0: Patients undergoing biopsy who are deemed unlikely to have sufficient tissue to spare for research purposes (e.g., those whose tumors are in an eloquent brain location where all tissue taken must be used for diagnostic purposes).

• Phase I: Increase in steroid requirement within 7 days of study enrollment (stable or decreasing dose allowed).

• Phase I, Recurrent: Radiation within 6 months prior to study enrollment.

• Phase I, Recurrent: Surgery within 4 weeks of re-irradiation.

• Phase I, Newly Diagnosed: History of hypersensitivity reactions to temozolomide or any other ingredients in temozolomide and dacarbazine.

• Phase I, Newly Diagnosed: Prior chemotherapy or radiation therapy for glioblastoma or gliosarcoma.

Related Conditions & MeSH terms

• Astrocytoma
• Glioblastoma
• Gliosarcoma
• Newly Diagnosed Glioblastoma
• Recurrence
• Recurrent Glioblastoma
• Recurrent Gliosarcoma

Intervention

Drug:
• Mycophenolate Mofetil
500-2000mg orally twice daily, one week prior to re-resection (2 participants at each of 4 dose levels: 500mg, 1000mg, 1500mg and 2000mg)

Radiation:
• Radiation Therapy
40.5 Gy in 15 fractions

Procedure:
• Re-resection (as part of standard of care)
Re-resection or biopsy of tumor as part of standard of care

Drug:
• Temozolomide
Temozolomide capsules are an approved oral chemotherapeutic drug for the treatment of adult patients with newly diagnosed GBM/GS concomitantly with radiotherapy and then as adjuvant treatment. The dosing and timing of temozolomide therapy will be determined as per standard-of-care for the individual patient by the treating oncologist.
• Mycophenolate Mofetil
250-2000mg orally twice daily, one week prior to and concurrent with RT.
• Mycophenolate Mofetil
250-2000mg orally twice daily, one week prior to and concurrent with RT and cyclic chemotherapy with temozolomide.

Radiation:
• Radiation Therapy
60 Gy in 30 fractions

Locations

Country	Name	City	State
United States	University of Michigan Rogel Cancer Center	Ann Arbor	Michigan

Sponsors (2)

Lead Sponsor	Collaborator
University of Michigan Rogel Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of mycophenolic acid (MPA) in tumor tissue in Phase 0 participants	The concentration of MPA (the active metabolite of mycophenolate mofetil [MMF]) in tumor tissue, measured by mass spectrometry on a continuous scale after one week of MMF administration.; This measure includes all phase 0 participants.	At 1 week
Primary	Number of recurrent phase 1 participants who experience dose-limiting toxicities (DLTs) at each dose level	DLT will be defined based on the rate of drug related grade 3-5 adverse events experienced from the start of treatment with MMF and for up to 4 weeks after completion of MMF + radiation therapy (RT). Assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.; This measure includes only phase 1 participants with recurrent GBM/GS.	Up to 28 days following completion of MMF + RT (up to ~9 weeks)
Primary	Number of newly diagnosed phase 1 participants who experience dose-limiting toxicities (DLTs) at each dose level -- DLT1 period	DLT will be defined based on the rate of drug related grade 3-5 adverse events experienced from the start of treatment with MMF and for up to 4 weeks after completion of MMF + RT + TMZ. Assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.; This measure includes only newly diagnosed phase 1 participants.	Up to 28 days following completion of MMF + RT + TMZ (up to ~11 weeks)
Primary	Number of newly diagnosed phase 1 participants who experience dose-limiting toxicities (DLTs) at each dose level -- DLT2 period	DLT will be defined based on the rate of drug related grade 3-5 adverse events experienced during the first 2 cycles (8 weeks) of MMF with adjuvant TMZ. (The first cycle of MMF with adjuvant TMZ begins 28 days post-RT.) These will be assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.; This measure includes only newly diagnosed phase 1 participants.	During the first 2 cycles (8 weeks) of MMF with adjuvant TMZ (up to ~19 weeks)
Secondary	Concentrations of guanosine triphosphate (GTP) in tumor tissue in Phase 0 participants	The concentrations of GTP in tumor tissue, measured by mass spectrometry on a continuous scale.; This measure includes all phase 0 participants.	After one week of MMF administration
Secondary	Adverse events associated with treatment in all Phase 1 Participants	Toxicities at each dose level will be tabulated, categorized by grade and attribution.; This measure includes all phase 1 participants.	Up to 28 days following completion of MMF + RT (up to ~9 weeks)
Secondary	Adverse events associated with treatment in newly diagnosed phase 1 participants	Toxicities at each dose level will be tabulated, categorized by grade and attribution.; This measure includes only newly diagnosed phase 1 participants.	Up to 28 days following completion of MMF with adjuvant temozolomide (up to ~15 months)
Secondary	Overall Response Rate in phase 1 participants with recurrent GBM/GS	Determined by modified Response Assessment for Neuro-Oncology (mRANO) criteria. The number and proportion of patients with progressive disease, stable disease, partial and complete response will be calculated for each dose level and overall.; This measure includes only phase 1 participants with recurrent GBM/GS.	Until study stops or death; up to approximately 3 years.
Secondary	Median Progression Free Survival (PFS) in phase 1 participants with recurrent GBM/GS	PFS defined as time from date of registration to the date of documented progressive disease, other disease related therapy or death. Determined by mRANO criteria.; This measure includes only phase 1 participants with recurrent GBM/GS.	Until study stops or death; up to approximately 3 years.
Secondary	Median Freedom from Local Progression (FFLP) in phase 1 participants with recurrent GBM/GS	FFLP defined as time from date of registration to the date of documented local progressive disease. Determined by mRANO criteria.; This measure includes only phase 1 participants with recurrent GBM/GS.	Until study stops or death; up to approximately 3 years.
Secondary	Median Overall Survival (OS) in phase 1 participants with recurrent GBM/GS	OS defined as time from date of registration to date of death or last follow up. Determined by Kaplan Meier method.; This measure includes only phase 1 participants with recurrent GBM/GS.	Until study stops or death; up to approximately 3 years.